Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy

Jeremy C. Borniger, William H. Walker II, Monica M. Gaudier-Diaz, Curtis J. Stegman, Ning Zhang, Jennifer L. Hollyfield, Randy J. Nelson & A. Courtney DeVries

Many cytotoxic chemotherapeutics elicit a proinflammatory response which is often associated with chemotherapy-induced behavioral alterations. The immune system is under circadian influence; time-of-day may alter inflammatory responses to chemotherapeutics. We tested this hypothesis by administering cyclophosphamide and doxorubicin (Cyclo/Dox), a common treatment for breast cancer, to female BALB/c mice near the beginning of the light or dark phase. Mice were injected intravenously with Cyclo/Dox or the vehicle two hours after lights on (zeitgeber time (ZT2), or two hours after lights off (ZT14). Tissue was collected 1, 3, 9, and 24 hours later. Mice injected with Cyclo/Dox at ZT2 lost more body mass than mice injected at ZT14. Cyclo/Dox injected at ZT2 increased the expression of several pro-inflammatory genes within the spleen; this was not evident among mice treated at ZT14. Transcription of enzymes within the liver responsible for converting Cyclo/Dox into their toxic metabolites increased among mice injected at ZT2; furthermore, transcription of these enzymes correlated with splenic pro-inflammatory gene expression when treatment occurred at ZT2 but not ZT14. The pattern was reversed in the brain; pro-inflammatory gene expression increased among mice injected at ZT14. These data suggest that inflammatory responses to chemotherapy depend on time-of-day and are tissue specific.

The toxicity of over 40 anticancer drugs, including cytostatics, cytokines, and targeted biological agents, is largely modified by circadian timing. The DNA intercalator doxorubicin and the alkylator cyclophosphamide show marked circadian variation in toxicity and tolerability. In the case of doxorubicin, these circadian effects persist in constant darkness or constant light, eliminating the covariate of masking by darkness or light. As circadian physiology between nocturnal rodents and diurnal humans is nearly 12 h out of phase, drug chronopharmacology typically displays opposite patterns between these species.

Cancer chronotherapy depends on administration of treatment at times that coincide with optimal drug metabolism and effects on cell cycle progression, DNA repair, and apoptosis. Additionally, several studies have demonstrated that peripherally administered cancer chemotherapeutics cause a peripheral and central inflammatory response. Inflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α) display a circadian rhythm in production and secretion, peaking during the early inactive phase coinciding with sleep onset, although organ- and cell-type deviations exist. Scheving and colleagues demonstrated a several-fold greater efficacy of doxorubicin-cyclophosphamide in male mice treated at ZT13 [zeitgeber time (ZT); 1 h into active phase] as compared to ZT1 (1 h into inactive phase); the mechanisms may relate to enhanced cytokines production at ZT1, that could then both disrupt the immune response of the host and accelerate cancer growth.

It remains unknown whether inflammatory responses to chemotherapeutics are altered by the timing of drug administration throughout the day, and whether the inflammatory response is linked to 'time-of-day dependent' side effects of treatment. One recent study examined transcript changes in the liver of mice administered various doses of cyclophosphamide (Cyclo) during the mid-day and mid-night (ZT 8 and ZT 20). Genes involved in immune responses were significantly upregulated by cyclophosphamide only in the group that was administered the
drug during the light phase, suggesting that hepatic immune responses to cyclophosphamide are under circadian control. It is also unknown whether similar responses occur centrally, in other organs, or with different chemotherapeutic regimens. We hypothesized that time-of-day influences inflammatory responses to cytotoxic chemotherapy. To test this hypothesis, we administered a cocktail of cyclophosphamide/doxorubicin (Cyclo/Dox; IV) at two different times of day (shortly after onset of light, and shortly after onset of dark) to female ovariectomized mice, and collected tissue/serum 1, 3, 9, and 24 hours later (experimental design: Fig. 1). We predicted that mice administered doxorubicin/cyclophosphamide chemotherapy at the beginning of their normally inactive phase (ZT 2) would display an exaggerated inflammatory response compared to mice injected at the beginning of their normally active phase (ZT 14).

Methods

Animals. Adult female BALB/c mice (>8 wks; Charles River Laboratories, Wilmington, MA, USA) were used in the experiments described herein. All mice were allowed to acclimate to our facility for 1 wk after arrival, and then were ovariectomized to eliminate the covariate of acute ovarian failure in response to chemotherapy. All surgeries were conducted using aseptic technique by an experienced surgeon (NZ), and mice were supplied analgesia (0.05 mg/kg buprenorphine, SC) and post-operative warmth (cage placement on a heating pad) until mobile. Ibuprofen (~30 mg/kg) was supplied in the drinking water for 5 days following surgery for further analgesia. Mice were group housed (4/cage) for 2 wks prior to experimental assignment. Mice were supplied ad libitum food (Harlan Teklad #7912) and filtered tap water, as well as a cotton nestlet. Cages were changed weekly. Mice were maintained on a 12:12 light/dark cycle. Body mass measures were obtained on the day prior to injection, and then at tissue collection 1, 3, 9, and 24 h post-injection. All experiments were approved and carried out in accordance with guidelines set by The Ohio State University Institutional Animal Care and Use Committee (IACUC).

Agent Administration. At ZT 2 (2 h after lights ON) or ZT 14 (2 h after lights OFF), mice were brought into an adjacent procedure room, briefly restrained in a conical tube, and injected intravenously (tail vein) with a cocktail of 13.5 mg/kg doxorubicin and 135 mg/kg cyclophosphamide or saline vehicle as previously described. This drug cocktail is commonly used as adjuvant treatment for localized breast cancer, as well for the treatment of metastatic disease. Dosing was determined from 75% of the human equivalent dose based on a body surface area equation. Injections at ZT 14 were completed under dim (<5 lux) red light to prevent circadian disruption by short-wavelength light.

Tissue Collection. Mice were rapidly euthanized via cervical dislocation and decapitation 1, 3, 9, and 24 h after agent administration. Whole brain, spleen and liver were collected on ice into 1.5 mL polypropylene tubes containing RNA-Later Reagent. Mice were sacrificed by short-wavelength light. A subset of the samples (111/128) had ≥4/group/timepoint). RNA was extracted using TRIzol reagent (Life Technologies, Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions. RNA pellets were resuspended in sterile, RNase-free water and quality and quantity were determined using a spectrophotometer. cDNA was synthesized using M-MLV reverse transcriptase. 20 ng of subsequent cDNA template was used in each qPCR reaction. Inventoried primer/probe pairs from Applied Biosystems (Life Technologies) were used (information available in Table 1). Probes that span exons were chosen to prevent amplification of residual gDNA. Taqman Fast Advanced Master Mix (Life Technologies) containing AmpliTaq Fast DNA polymerase was used in a 20 μL duplex reaction containing target primer/probes and one for the endogenous control eukaryotic 18s rRNA. The 2-step RT-qPCR cycling conditions were: a holding stage of 95°C for 20 s, 40 cycles of 95°C for 3 s, and then 60°C for 30 s. Relative gene expression was calculated using a relative standard curve, normalized to 18s rRNA signal.

Cytokine Multiplex Assay. To examine cytokine and chemokine concentrations in serum, a multiplex inflammatory panel was conducted (V-Plex proinflammatory panel 1, Meso-Scale Discovery, Rockville, Maryland, USA) according to the manufacturer’s instructions. This kit measures protein levels of IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO (CXCL1), and TNF-α. A subset of the samples (111/128) had sufficient serum to be included in the multiplex assay; n ≥4/group/timepoint).

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR). RNA was extracted using TRIzol reagent (Life Technologies, Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions. RNA pellets were resuspended in sterile, RNase-free water and quality and quantity were determined using a spectrophotometer. cDNA was synthesized using M-MLV reverse transcriptase. 20 ng of subsequent cDNA template was used in each qPCR reaction. Inventoried primer/probe pairs from Applied Biosystems (Life Technologies) were used (information available in Table 1). Probes that span exons were chosen to prevent amplification of residual gDNA. Taqman Fast Advanced Master Mix (Life Technologies) containing AmpliTaq Fast DNA polymerase was used in a 20 μL duplex reaction containing target primer/probes and one for the endogenous control eukaryotic 18s rRNA. The 2-step RT-qPCR cycling conditions were: a holding stage of 95°C for 20 s, 40 cycles of 95°C for 3 s, and then 60°C for 30 s. Relative gene expression was calculated using a relative standard curve, normalized to 18s rRNA signal.

Figure 1. Experimental Design. Mice were intravenously injected with Cyclo/Dox or the vehicle at ZT 2 or ZT 14. Tissue was collected 1, 3, 9, and 24 h later from each of these time points. Blue arrows denote the 24 h tissue collection time point.
F1,98 MAC-1 (aka ITGAM) (of splenic IL-1
spleen as an index of the peripheral immune response (Fig. 3). Chemo-treated animals increased gene expression

Table 1. Primer/probe information for targets used in qPCR.

| Gene | Assay ID | Amplicon Size (bp) |
|------|----------|--------------------|
| Il6  | Mm00446190_m1 | 78                 |
| Il1b | Mm00434228_m1 | 90                 |
| Socs3| Mm01249143_g1 | 113                |
| Tnf  | Mm00443258_m1 | 81                 |
| Il1r | Mm00446186_m1 | 80                 |
| Cbr1 | Mm04207333_g1 | 83                 |
| Cyp2b10 | Mm00456588_mH | 88              |
| Cyp3a13 | Mm00484110_m1 | 88               |
| Igam | Mm00434455_m1 | 69                 |
| Stat3| Mm01219775_m1 | 75                 |
| Nos2 (iNos) | Mm00440502_m1 | 66                  |
| Ccl2 | Mm00441242_m1 | 74                 |
| 18s  | Hs99999901_s1 | 187               |

Corticosterone Enzyme Immunoassay (EIA). Serum corticosterone was determined using an enzyme immunoassay kit (DetectX, K014-H15, Arbor Assays, Michigan, USA). In brief, samples were diluted with dissociation reagent and assay buffer 1:100, and assayed in duplicate. Plates were read on a plate reader at 450 nm, and concentrations were determined using a 4-parameter logistic curve plotting unknowns against standard corticosterone values. This assay was run after using a significant amount of serum for the multiplex cytokine analyses described above, and therefore not all samples contained sufficient serum to be assayed for corticosterone (77/128). Therefore, the results presented provide only a snapshot of corticosterone concentrations at 24 h post-injection. The average intra-assay coefficient of variation was 8.17% and the inter-assay %CV was 7%.

Statistical Analyses. Factorial ANOVAs with treatment, injection time, and time after injection as fixed factors were used. To control for circadian variation in gene expression, data were analyzed (and displayed) as fold change from time-matched vehicle controls. When significant F values were detected, post-hoc univariate ANOVAs were completed to examine time-point specific differences between groups. Data that did not show equal variance were subjected to non-parametric tests (i.e., Mann-Whitney U). Percent change in body mass measures from baseline between each group was compared using a paired-samples t-test. Values for each variable that fell ≥2 standard deviations outside of the group mean (Z-score) were considered outliers and removed from analyses a priori. For the spleen, liver, hypothalamus, and hippocampus, 3, 7, 4, and 4 samples (respectively) failed to amplify during PCR, and their data were therefore not analyzed. Outliers were determined within each experimental group (that is, split by time of injection (ZT 2 vs. 14), injection type (chemo vs. veh), and tissue collection to amplify during PCR, and their data were therefore not analyzed. Outliers were determined within each experimental group. After this, each group had between 6–8 animals for the spleen, 5–8 animals for the liver, and 5–8 animals for the brain per gene analyzed; no more than 1 animal/timepoint/treatment was excluded by Z-score analysis. Final sample sizes are listed in the figure legends. Body mass for one mouse was not recorded prior to sample collection and is therefore not included in the analysis. All statistics were completed using SPSS Statistics version 23 (IBM, Armonk, NY) and GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Mean differences were considered statistically significant when p ≤ 0.05.

Results

Time of Injection Alters Body Mass Loss After Cyclo/Dox Administration. Due to normal circadian variation in food intake and activity that can affect body mass, analyses were conducted on percent change in body mass from baseline. 24 h after agent administration, ZT 2 treated animals lost significantly more weight (−5.603 ± 2.85%) than their counterparts injected at ZT 14 (−2.02 ± 2.48%; t = 3.147, p = 0.016) compared to their time-matched vehicle controls (Fig. 2).

Injection Time Alters Splenic Cytokine Transcription. Cytokine transcription was measured in the spleen as an index of the peripheral immune response (Fig. 3). Chemo-treated animals increased gene expression of splenic IL-1β (F1,95 = 46.005, p < 0.0001), IL-6 (F1,97 = 11.97, p < 0.001), TNF-α (F1,101 = 22.551, p < 0.0001), SOCS3 (F1,101 = 32.86, p < 0.0001), IL-1ra (F1,100 = 22.164, p < 0.0001), iNOS (F1,98 = 6.243, p < 0.05), but not MAC-1 (aka ITGAM) (F1,98 = 1.461, p > 0.05). There was an interaction between injection time and treatment in IL-1β (F1,95 = 10.689, p < 0.005), TNF-α (F1,101 = 6.917, p < 0.01), SOCS3 (F1,101 = 11.6, p < 0.001), IL-1ra (F1,100 = 10.532, p < 0.005), iNOS (F1,98 = 10.539, p < 0.005), but not IL-6 (F1,97 = 1.308, p > 0.05) or MAC-1 (F1,98 = 1.293, p > 0.05) expression, such that animals injected at ZT 2 displayed elevated responses to chemotherapy injection compared to animals injected at ZT 14. Corticosterone concentrations were altered by injection time and treatment 24 h post-injection (F1,123 = 3.9, p < 0.05); corticosterone was elevated at ZT 14 compared to ZT 2 in vehicle-treated mice (Tukey HSD post-hoc; p < 0.05), and chemotherapy treatment increased circulating corticosterone concentrations in mice injected at ZT 2 (p < 0.05), but not ZT 14 (p > 0.05) (Fig. 3i). These data suggest that injection time has differential effects on the glucocorticoid response to chemotherapy treatment.
IL-1ra: A similar pattern was observed for IL-6: R \( \beta < 0.05 \), an effect not evident in Cyp3a13 (p \( \beta > 0.05 \)), but an interaction between treatment and injection time (F \( \beta,95 = 8.565, p < 0.005 \)), an effect not evident in Cyp3a13 (p \( \beta > 0.05 \)) or Cbr1 (p \( \beta > 0.05 \)) expression. The activity of Cyp2a10 positively correlated with the splenic expression of many proinflammatory cytokines in mice that were injected at ZT 2 (IL-6: R = 3.26, p < 0.05; IL-1β: R = 0.579, p < 0.0001; SOCS3: R = 0.314, p < 0.05; TNF-α: R = 0.387, p < 0.01; IL-1α: R = 0.348, p < 0.05), but not in mice injected at ZT 14 (except IL-1β: R = 0.3, p < 0.05) (Fig. 6a–c). A similar pattern was observed for Cyp3a13 (ZT 2: iNOS: R = 0.418, p < 0.01; SOCS3: R = 0.295, p < 0.05; TNF-α: R = 0.396, p < 0.01; IL-1α: R = 0.353, p < 0.05; IL-14: all correlations p > 0.05), but not for Cbr1 (excepting ZT 2 iNOS: R = 0.295, p < 0.05; ZT 14: All genes p > 0.05). Liver transcription of these enzymes was related in a similar fashion to hypothalamic cytokine transcription, with Cyp2b10 correlating with several genes in mice injected at ZT 2 (Fig. 6d–f) (IL-1β: R = 0.346, p < 0.05; IL-6: R = 0.323, p < 0.05; STAT3: R = 0.318, p < 0.05; CCL2: R = 0.29, p < 0.05; ZT 14: all genes p > 0.05).
p < 0.05), but not ZT 14 (p > 0.05 in all gene examined). Cyp3a13 transcription was associated with hypothalamic IL-6 expression in mice injected at ZT 2 compared to those administered the same dose at ZT 14. By contrast, expression of Cbr1 was positively correlated with hypothalamic IL-6 only in mice injected at ZT 2 (R = 0.34, p < 0.05; ZT 14: all genes examined p > 0.05).

Time of Injection Does Not Alter Circulating Cytokine Levels. There was a significant increase in serum IL-6 (F(1,94) = 38.485, p < 0.0001) and CXCL1 (aka KC/GRO) (F(1,98) = 19.19, p < 0.0001) concentrations, but not IFN-γ, IL-10, IL-13, IL-2, IL-5, or TNF-α (p > 0.05 in all cases), among chemo-treated mice compared to vehicle-treated animals. There was no interaction between injection time and treatment in any of the serum proteins examined (p > 0.05 in all cases) (Fig. 7).

Discussion
Together, the data presented here demonstrate tissue-specific, time-of-day-dependent changes in inflammatory responses to cytotoxic chemotherapy. Mice injected with Cyclo/Dox at ZT 2 exhibited no increase in hypothalamic IL-1β, TNF-α, IL-6, CCL2, STAT3, or SOCS3, a downstream target of JAK/STAT signaling, compared to vehicle-treated animals. Animals treated at ZT 14, however, showed a biphasic expression of these genes in the hypothalamus, with peaks at 3 and 24 h after injection (Fig. 4). This pattern was similar in the hippocampus, where animals injected at ZT 14 increased hippocampal IL-1β and TNF-α 3–9 h following injection, a pattern not evident in mice injected at ZT 2 (Fig. 4h,i). The induction of inflammatory mediators within the brain displayed the opposite pattern from the spleen (Fig. 4). This difference between peripheral and central inflammatory responses to chemotherapy highlights the need for a comprehensive understanding of the impact of chemotherapy on the immune system.
signaling in response to chemotherapy may depend on clock gene activity within brain microglia and peripheral macrophages, which contain autonomous clocks that are 6–8 h out of phase with each other. Additionally, central clocks and those in peripheral organs are ~4 h out of phase, reflecting the master/slave oscillator relationship between them. These data also highlight the notion that peripheral responses to an immune challenge cannot be considered a reliable indicator of the central response (e.g., see ref. 24). Results such as these provide additional evidence for the pleiotropic effects of cytokines, dependent on time-of-day and tissue specificity.

There also appears to be temporal variation in the activation of metabolic pathways of cyclophosphamide and doxorubicin. Cyclophosphamide is a prodrug that requires metabolic activation. Cyp2b10 is responsible for the conversion of cyclophosphamide into a toxic metabolite, 4-hydroxycyclophosphamide (4-OH), whereas Cyp3a13 contributes to both activation and inactivation of cyclophosphamide through conversion to 4-OH and the inactive compound dechloroethylcyclophosphamide (DCE; Fig. 5). The activity of these enzymes significantly contributes to the toxicity of cyclophosphamide, and influences its tolerability. In the present study, mice injected at ZT 2 had increased Cyp2b10 gene expression (Fig. 5), which may suggest increased production of toxic 4-hydroxycyclophosphamide (4-OH) relative to mice treated at ZT 14. Consistent with this observation, a previous study reported increased mortality among mice treated with cyclophosphamide between ZT 22 and ZT 2 relative to mice treated between ZT 10 and ZT 14. This study, as well as a more recent one, reported no temporal effects on cyclophosphamide metabolism, however, these studies did not examine enzyme activity or serum metabolite concentration later than 4 hours after injection, while in the present study, the temporal effect on the metabolic pathway did not emerge until >9 hours after injection (Fig. 5). We also observed a time-of-day effect in doxorubicin (DOX) metabolism. An initial step in DOX metabolism is its reduction to doxorubicinol (DOX-OL). DOX-OL is a less effective anti-neoplastic agent, and displays a greater capacity to induce cardiotoxicity. This initial conversion of DOX→DOX-OL is catalyzed by carbonyl reductase 1 (Cbr1), primarily in the liver. Mice that received chemotherapy at ZT 2 elevated Cbr1 transcription at 24 h after injection compared to mice that received

Figure 4. Time-of-day alters brain cytokine/chemokine expression in response to cytotoxic chemotherapy.

Animals injected at ZT 14 displayed elevated hypothalamic (a) IL-1β, (B) TNF-α, (c) IL-6, (d) STAT3, (e) SOCS3, and (f) CCL2 expression over time in response to chemotherapy compared their counterparts injected at ZT 2 (g) Average hypothalamic values across the entire post-injection timeframe. (h) Hippocampal IL-1β and (i) TNF-α expression. (n=5–8/group/timepoint; *p < 0.05, **p < 0.01 in relation to the time-matched vehicle control; Error bars represent S.E.M). The dotted line at y = 1 represents normalized vehicle values.
treatment at ZT 14 (Fig. 5a). Taken together, the data suggest that enhanced inflammation in mice injected at ZT 2 may reflect increased production of toxic drug metabolites 4-OH and DOX-OL. In support of this explanation, splenic inflammation was positively correlated with liver enzyme activity only in the mice administered Cyclo/Dox at ZT 2, but not ZT 14 (Fig. 6). This ZT 2 specific correlation was also observed within the hypothalamus (Fig. 6d–f), even though inflammation in this tissue was enhanced in mice injected at ZT 14 relative to ZT 2, indicating that liver metabolism of Cyclo/Dox may be uncoupled from inflammatory processes occurring in the brain. Together, these data support the hypothesis that time-of-day dependent effects of administration likely depend on downstream cyclophosphamide actions on the DNA damage response, inflammation, or additional pathways.

A potential contributor to the phenotype we observed could be sleep disruption. We have previously reported marked sleep fragmentation after administration of the same chemo regimen used in the present study. As sleep disruption elicits an inflammatory response, this may have contributed to the enhanced splenic inflammation observed in animals injected at ZT 2. Additionally, glucocorticoid concentrations peak during the early active phase in nocturnal rodents, and they are negative regulators of inflammation, acting through multiple mechanisms. Therefore, elevated baseline concentrations of glucocorticoids in mice injected at ZT 14 may have contributed to the dampened inflammatory response observed in the spleen, a pattern observed in the present study (Fig. 3i). Indeed, morning administration of doxorubicin and evening administration of cisplatin is much better...
tolerated than the opposite administration schedule in humans with advanced ovarian cancer; it is hypothesized that peak glucocorticoid concentrations at the time of doxorubicin administration may buffer the inflammatory response to the drug.

Periphery-to-brain inflammatory signaling can be accomplished through several mechanisms. Because we did not observe a change in serum cytokine responses to chemotherapy dependent on time-of-day (Fig. 7), it is unlikely that humoral signaling is the primary means by which chemotherapy elicits differential hypothalamic effects at ZT 2 and ZT 14. Alternatively, transcription of the monocyte recruiting chemokine CCL2 in the hypothalamus was elevated following administration of chemotherapy at ZT 14, but not ZT 2 (Fig. 4f). Recently, direct interactions among the circadian clock and CCL2 have been reported to mediate time-of-day dependent responses to peripheral endotoxin administration, with peak hypothalamic CCL2 expression during the dark

Figure 6. Splenic and hypothalamic inflammatory responses to chemotherapy are related to liver enzyme transcription only in mice injected at ZT 2. Pearson correlations between liver enzymes that metabolize cyclophosphamide: Cyp2b10, Cyp3a13 and splenic (a,b) and hypothalamic (d,e) inflammatory mediators. Cbr1, responsible for doxorubicin metabolism and its relation to splenic (c) and hypothalamic (f) inflammatory gene transcription after chemotherapy at ZT 2 or ZT 14. (*p < 0.05, **p < 0.01).
Therefore, the phenotype we observed within the hypothalamus may be driven by time-of-day dependent recruitment of peripheral monocytes/macrophages into the brain.

Several intriguing questions remain regarding the interactions among chemotherapy and other cancer- and treatment-related factors. For example, we chose to begin this line of inquiry by examining the effects of chemotherapy in non-tumor bearing mice because cyclophosphamide and doxorubicin combination therapy is typically given in an adjuvant setting once the tumor has been resected. However, additional studies are necessary to determine whether a prior or current tumor sensitizes or causes a temporal shift in inflammatory responses to doxorubicin and cyclophosphamide. Comparing responses in mice that are tumor-naive, tumor-bearing, versus tumor-resected will be critical for assessing whether tumors and/or the surgery associated with their removal prime inflammatory responses to chemotherapy and if so, how long after tumor removal the effects persist.

Indeed, the primary reason the current study was conducted in BALB/C mice is that there are well-characterized metastatic and non-metastatic mammary tumor cell lines that are specific to this mouse strain (e.g., 4T1, 67NR, 4T07). Despite muted nightly melatonin rhythms, BALB/C mice display robust rhythms in immune cell activity, cytokine secretion, and response to endotoxin challenge. For instance, BALB/C mice display robust time-of-day dependent changes in LPS-responsiveness dependent on diurnal variations in NF-κB activity. Additionally, circadian sensitivity to cyclophosphamide has been demonstrated in C57BL/6J mice, which also lack robust circadian rhythms in melatonin production and secretion, suggesting that a robust melatonin signal is not required for the time-of-day dependent effects of cyclophosphamide. Regardless, further studies should investigate a potential role for endogenous melatonin in buffering inflammatory responses to cytotoxic chemotherapy.

The predictive value of rodent studies for human inflammatory conditions also has become a topic of debate recently. How closely the liver, spleen, and brain inflammatory gene expression data collected in mice in the current study reflect changes occurring in human cancer patients is not ethically determinable with currently available technology. However, our data demonstrate that the potential exists for circadian differences in inflammatory and metabolic responses to a common chemotherapy regimen, and also that it should not be assumed that
all tissues respond similarly. Nonetheless, the temporal aspects of chemotherapy treatment in patients with breast cancer is worth exploring given that there is a growing literature demonstrating diurnal variation in immune parameters associated with inflammatory diseases and experimental endotoxin exposure in people.\(^{19,20}\)

In sum, our data demonstrate time-of-day-dependent changes in inflammatory responses to cytotoxic chemotherapy. Specifically, splenic inflammatory responses to cyclophosphamide and doxorubicin are maximal when the drugs are administered during the early inactive phase (ZT 2), and lowest when administered during the early active phase (ZT 14). By contrast, inflammatory gene expression within the hypothalamus displays the reciprocal pattern, as mice injected at ZT 14 show an enhanced hypothalamic inflammatory response compared to those injected at ZT 2. Additionally, the activity of enzymes responsible for the conversion of doxorubicin and cyclophosphamide into their toxic metabolites displays differential induction dependent on time-of-day, and their activity correlates with splenic and hypothalamic inflammatory responses only in mice injected during the early inactive phase. These data further add to the growing literature on cancer ‘chronotherapy’, and highlight inflammatory responses to treatment as a proximate cause of chemotherapy-induced side effects dependent on time of drug administration.

References
1. Lévi, F., Olyar, A., Dulong, S., Innominato, P. F. & Clairambault, J. Circadian timing in cancer treatments. *Annu Rev Pharmacol Toxicol* **50**, 377–421 (2010).
2. Granda, T. G. et al. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. *Cancer Res* **61**, 1996–2001 (2001).
3. Gorbacheva, V. Y. et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. *Proc Natl Acad Sci USA* **102**, 3407–12 (2005).
4. Sothern, R., Halberg, F. & Hrushesky, W. Circadian stage not time-of-day characterizes doxorubicin susceptibility rhythm of mice in continuous light. *Annu Rev Pharmacol Toxicol* **5**, 385 (1988).
5. Levi, F. & Schibler, U. Circadian rhythms: mechanisms and therapeutic implications. *Annu Rev Pharmacol Toxicol* **47**, 593–628 (2007).
6. Weymann, K. B., Wood, L. J., Zhu, X. & Marks, D. L. A role for orexin in cytotoxic chemotherapy-induced fatigue. *Brain Behav Immun* **37**, 84–94 (2014).
7. Smith, L. B. et al. The role of (L)-13 and TNF-α signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. *Brain Behav Immun* **36**, 68–76 (2014).
8. Elsee, C. R., Roberts, D. A., Druker, B. J. & Wood, L. I. Inhibition of p38 MAPK Suppresses Inflammatory Cytokine Induction by Etoside, 5-Fluorouracil, and Doxorubicin without Affecting Tumoricidal Activity. *PloS ONE* **3**, e2355, doi: 10.1371/journal. pone.0002355 (2008).
9. Wong, L. J. et al. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. *Cancer Biol Ther* **14**, 56–63 (2013).
10. Borniger, J. C., Gaudier-Diaz, M. M., Zhang, N., Nelson, R. J. & DeVries, A. C. Cytotoxic chemotherapy increases sleep and sleep fragmentation in non-tumor-bearing mice. *Brain Behav Immun* **47**, 218–27 (2015).
11. Guan, Z. et al. Interleukin-6 levels fluctuate with the light–dark cycle in the brain and peripheral tissues in rats. *Brain Behav Immun* **19**, 526–9 (2005).
12. Fonken, L. K. et al. Microglia inflammatory responses are controlled by an intrinsic circadian clock. *Brain Behav Immun* **45**, 171–9 (2015).
13. Coogan, A. N. & Wyse, C. A. Neuroimmunology of the circadian clock. *Brain Res* **1232**, 104–12 (2008).
14. Besedovsky, L., Lange, T. & Born, J. Sleep and immune function. *Eur J Physiol* **463**, 121–37 (2012).
15. Schering, L. E., Burns, E. R., Pauly, J. E. & Halberg, F. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with Adriamycin and cyclophosphamide. *Cancer Res* **40**, 1511–1515 (1980).
16. Van Dycke, K. C. et al. A day and night difference in the response of the hepatic transcriptome to cyclophosphamide treatment. *Arch Toxicol* **89**, 221–31 (2015).
17. Poniatowski, B. C., Grimm, P. & Cohen, G. Chemotherapy-induced menopause: a literature review. *Cancer Invest* **19**, 641–8 (2001).
18. Molina, J. R., Barton, D. L. & Loprinzi, C. L. Chemotherapy-induced ovarian failure. *Drug Safety* **28**, 401–16 (2005).
19. Shulman, L. N. et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). *J Clin Oncol* **19**, 2311–2317 (2001).
20. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. *FASEB J* **22**, 659–61 (2008).
21. Keller, M. et al. A circadian clock in macrophages controls inflammatory immune responses. *Proc Natl Acad Sci USA* **106**, 21407–12 (2009).
22. Balsalobre, A., Damiola, F. & Schibler, U. A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell* **99**, 929–37 (1998).
23. Balsalobre, A. Clock genes in mammalian peripheral tissues. *Cell Tissue Res* **309**, 193–9 (2002).
24. Karelin, K. et al. Social isolation alters neuroinflammatory response to stroke. *Proc Natl Acad Sci USA* **106**, 5895–900 (2009).
25. Kassner, N. et al. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. *Drug Metab Dispos* **362**, 113–20 (2008).
26. Faraut, B., Boujdjelta, K. Z., Vanhamme, L. & Kerkhofs, M. Immune, inflammatory and cardiovascular consequences of sleep restriction and recovery. *Sleep Med Rev* **16**, 137–49 (2012).
27. Ashley, N. T., Sams, L. W., Brown, A. C. & Dumaine, J. E. Novel environment influences the effect of paradoxical sleep deprivation upon brain and peripheral cytokine gene expression. *Neurosci Lett* **615**, 55–59 (2016).
28. Donn, J. K. et al. Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. *PLOS ONE* **9**, e87999 (2014).
29. Scheiermann, C., Kuniyasu, Y. & Fenrette, P. S. Circadian control of the immune system. *Nat Rev Immunol* **13**, 190–8 (2013).
30. Barnes, P. J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci* **94**, 557–72 (1998).
31. Hrushesky, W. J. Circadian timing of cancer chemotherapy. *Science* **228**, 73–75 (1985).
32. Quinn, N. & Banks, W. A. Brain-immune communication pathways. *Brain Behav Immun* **21**, 727–35 (2007).
33. Duhart, J. M., Brocardo, L., Fedele, M. L., Guglielmotti, A. & Golombek, D. A. CCL2 mediates the circadian response to low dose endotoxin. *Neuropharmacology* **108**, 373–81 (2016).
34. Vrijenhoek, B. et al. Daily variations in pineal melatonin concentrations in inbred and outbred mice. *J Biol Rhythms* **13**, 403–409 (1998).
35. Spengler, M. L. et al. Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. *Proc Natl Acad Sci USA* **109**, E2457–2465 (2012).
36. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci USA* **110**, 3507–3512 (2013).
37. Takao, K. & Miyakawa, T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA 112, 1167–1172 (2015).
38. Shay, T., Lederer, J. A. & Benoist, C. Genomic responses to inflammation in mouse models mimic humans: we concur, apples to oranges comparisons won't do. Proc Natl Acad Sci USA 112, E346 (2015).
39. Alamili, M., Bendtzen, K., Lykkesfeldt, J., Rosenberg, J. & Gögenur, I. Pronounced inflammatory response to endotoxaemia during nighttime: a randomised cross-over trial. PloS One 9, e87413 (2014).
40. Petrovsky, N., McNair, P. & Harrison, L. C. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 10, 307–312 (1998).

Acknowledgements
We thank Trina Wemlinger and the research support services at the OSU Center for Clinical and Translational Science (supported by award # UL1TR001070) for assistance with the V-plex multiplex assay. We further thank Liane Davila-Martin and Kyra Ungerleider for assistance in RNA extraction and qPCR and the University Laboratory Animal Resource (ULAR) personnel for providing excellent care to the animals used in the present study. This study was funded by NIH R21CA191846 and R01CA194924 and an OSU Presidential and Pelotonia Graduate Fellowship to JCB.

Author Contributions
J.C.B. designed experiments, conducted experiments, analyzed data, wrote the paper; W.H.W. designed experiments, conducted experiments, analyzed data, edited the paper; M.M.G.D. conducted experiments, edited the paper; C.J.S. conducted experiments, edited the paper; N.Z. conducted experiments; J.L.H. conducted experiments; R.J.N. designed experiments, wrote the paper; A.C.D. designed experiments, wrote the paper.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Borniger, J. C. et al. Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy. Sci. Rep. 7, 41220; doi: 10.1038/srep41220 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017